MBHB Associate Taylor Weilnau Comments on the Supreme Court’s Review of Hikma v. Amarin in Bloomberg Law

In Bloomberg Law, MBHB Associate Taylor Weilnau shares her thoughts on the how the U.S. Supreme Court’s review of the Hikma v. Amarin “skinny labeling” case could impact both branded and generic drug companies, as well as patients and physicians. Read more here.